

Supplemental Table S4. Risk Factors for All Fractures and Site-Specific Fractures in the Study Participants

Variable	All fracture		Vertebral fracture		Non-vertebral fracture		Hip fracture		Non-hip and non-vertebral fractures	
	Multivariable sHR (95% CI)	P value	Multivariable sHR (95% CI)	P value	Multivariable sHR (95% CI)	P value	Multivariable sHR (95% CI)	P value	Multivariable sHR (95% CI)	P value
Acromegaly group	0.99 (0.66–1.47)	0.940	1.16 (0.66–2.05)	0.612	0.82 (0.47–1.45)	0.499	2.58 (1.19–5.59)	0.017 ^a	0.40 (0.16–0.96)	0.041 ^a
Socioeconomic status										
Low	0.98 (0.82–1.18)	0.841	1.05 (0.79–1.40)	0.715	0.97 (0.76–1.23)	0.785	1.27 (0.76–2.13)	0.357	0.91 (0.70–1.19)	0.493
Middle	1 (Ref.)		1 (Ref.)		1 (Ref.)		1 (Ref.)		1 (Ref.)	
High	0.84 (0.71–0.99)	0.038 ^a	0.90 (0.69–1.16)	0.408	0.81 (0.65–1.002)	0.053	0.85 (0.52–1.38)	0.513	0.79 (0.62–1.01)	0.057
Baseline comorbidities										
Type 2 DM	1.08 (0.85–1.36)	0.531	0.86 (0.61–1.23)	0.415	1.28 (0.95–1.72)	0.101	1.55 (0.91–2.64)	0.109	1.17 (0.81–1.68)	0.404
Heart failure	1.08 (0.59–2.00)	0.798	1.40 (0.64–3.08)	0.400	0.71 (0.26–1.94)	0.504	0.47 (0.06–3.64)	0.466	0.85 (0.27–2.68)	0.784
Cardio-cerebrovascular disease	1.45 (1.08–1.94)	0.015 ^a	1.69 (1.13–2.51)	0.010 ^a	1.15 (0.75–1.75)	0.525	1.83 (0.91–3.70)	0.091	0.91 (0.53–1.57)	0.732
COPD	1.11 (0.85–1.46)	0.436	1.04 (0.69–1.55)	0.857	1.14 (0.80–1.62)	0.460	1.63 (0.87–3.02)	0.125	0.99 (0.65–1.52)	0.976
Rheumatoid arthritis	1.27 (0.86–1.87)	0.226	1.01 (0.53–1.92)	0.976	1.57 (1.00–2.49)	0.052	1.90 (0.74–4.90)	0.186	1.46 (0.86–2.45)	0.160
Chronic liver disease	1.22 (0.92–1.60)	0.168	1.27 (0.86–1.89)	0.230	1.19 (0.83–1.71)	0.354	0.72 (0.31–1.68)	0.442	1.35 (0.91–2.02)	0.136
CKD/ESRD	1.60 (0.80–3.22)	0.185	1.48 (0.53–4.13)	0.457	2.20 (1.00–4.84)	0.049 ^a	3.94 (1.30–11.90)	0.015 ^a	1.45 (0.48–4.41)	0.513
Previous fracture history	4.89 (3.59–6.67)	<0.001 ^a	5.49 (3.68–8.19)	<0.001 ^a	5.21 (3.53–7.70)	<0.001 ^a	6.44 (3.16–13.16)	<0.001 ^a	4.84 (3.08–7.62)	<0.001 ^a

sHR, sub-distribution hazard ratio; CI, confidence interval; DM, diabetes mellitus; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; ESRD, end-stage renal disease.

^aStatistical significance at $P < 0.05$.